KYBELLA ®

 

BOTHERED BY THE FULLNESS BENEATH YOUR CHIN?

* KYBELLA ® is the first and only FDA-approved injectable treatment to improve the appearance of moderate to severe fat beneath the chin (submental fullness) by physically destroying fat cells.

Results are represented over the course of treatment; not all treatments are shown. Up to 6 treatments may be administered, spaced no less than 1 month apart. In clinical trials, 59% of people treated with KYBELLA ® received all 6 treatments.

KYBELLA® (deoxycholicacid)injection10mg/mL Before-and-After Photos (Alisha 1)

KYBELLA® (deoxycholic acid) injection 10 mg/mL Indication and Important Safety Information

KYBELLA ® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA ® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

Contraindications

KYBELLA® is contraindicated in the presence of infection at the injection sites.

Warnings and Precautions

Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA ® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA ® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA ® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Adverse Reactions

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA ® full prescribing information.

BOOK AN APPOINTMENT

Are you ready to book an appointment? Try our easy and convenient online booking tool.

 

SANTÉ AESTHETICS & WELLNESS

We are conveniently located in the heart of Northwest Portland.

210 NW 17th Ave
Portland, OR 97209
Click Here for a Map

(971) 407-3066

Hours of Operation:
Tue-Sat 10am - 6pm
Sun-Mon By Appointment

 

PATIENT REVIEWS

InjectablesRahul dhiman